Ozempic and GLP-1 lawsuits: 4,025 injury cases are pending in federal court
As of October 1, 2026, 4,025 lawsuits claiming that Ozempic, Wegovy, Mounjaro and other GLP-1 drugs caused stomach and bowel injuries were pending in one federal case group (MDL 3094) in Philadelphia.
- 247 more claim sudden vision loss (NAION) in a second group, MDL 3163, before the same judge.
- These are allegations. No court has found Novo Nordisk or Eli Lilly liable, and both deny the stomach-injury claims.
- Separately, the FTC's case against Hims & Hers concerns billing, cancellation and privacy practices.
Counts come from the Judicial Panel on Multidistrict Litigation's pending-MDL report dated October 1, 2026.
Are the GLP-1 lawsuits a class action?
An MDL is not a class action. It coordinates related federal cases before one judge for pretrial proceedings. The court describes MDL 3094 as personal-injury actions. Class actions can sometimes be included within an MDL, so the terms are not interchangeable. The dated pending-case totals on this page are MDL case counts; they do not establish who qualifies for compensation.
Read the court's MDL explanation and the MDL 3094 court page for the procedural context.
Last updated: . This is a summary of the source-linked case records below, not legal advice or a complete enforcement inventory.
Case records and dated counts
Ozempic, Wegovy and Mounjaro stomach-injury claims (MDL 3094)
MDL ActiveThe plaintiffs allege that these GLP-1 drugs caused gastroparesis and other gastrointestinal injuries, and that the makers failed to warn about them.
Both defendant groups deny the allegations. The JPML counted 4,025 pending actions as of October 1, 2026.
The court held a Rule 702 (Daubert) hearing on expert evidence from September 14 to 18, 2026. No court has found the makers liable.
Source: Court's MDL 3094 page; counts from the JPML pending-MDL report
Vision-loss (NAION) claims against GLP-1 makers (MDL 3163)
MDL ActiveThe plaintiffs allege that Ozempic, Wegovy, Saxenda and Trulicity caused non-arteritic anterior ischemic optic neuropathy (NAION), a sudden loss of vision in one eye.
The JPML centralized the cases in Philadelphia on December 15, 2025, before the same judge as the stomach-injury MDL, and counted 247 pending actions as of October 1, 2026.
These are allegations, not findings.
Source: JPML transfer order, December 15, 2025
FTC and States v. Hims & Hers Health, Inc.
PendingOn July 29, 2026 the Federal Trade Commission, joined by the Utah Division of Consumer Protection and the People of the State of California acting through Los Angeles County Counsel Dawyn R. Harrison, filed a Complaint for Permanent Injunction, Monetary Judgment, Civil Penalty Judgment, and Other Relief against Hims & Hers Health, Inc. The complaint alleges the company fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling them they will be able to consult a medical provider first; that it made subscriptions difficult to cancel; and that it shared consumers' health information with Meta, Snap and other third parties despite claiming its services keep that information private.
Case status is Pending. These are allegations that have not been proven in court, and the company has not been found liable.
Hims and Hers are the two consumer brands of this defendant, and both of our review pages carry the same disclosure.
Source: FTC Legal Library case record
What This Means for Patients
If you experienced severe GI side effects
If you developed gastroparesis, severe stomach paralysis, bowel obstruction, or other serious GI injuries while taking Ozempic, Wegovy, Mounjaro, or Zepbound, you may be eligible to join the MDL.
Consult a personal injury attorney specializing in pharmaceutical litigation.
If your compounded medication was discontinued
Ask your prescriber and dispensing pharmacy why supply stopped and what treatment route is appropriate. Do not assume another compounded formulation is approved or suitable because it is described as reformulated.
Our provider listings describe available programs and their terms; they do not establish medical suitability or regulatory compliance.
How to verify your provider
Use our Safety Checker to review the public warning-letter and pharmacy-disclosure records we have collected.
It is a non-exhaustive research aid, not proof of FDA compliance or medical safety.
Where to go next
Need a program shortlist? Our 2-minute match quiz helps sort your preferences; it is not a safety assessment. Explore the public-record resources below for a different research step.